Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.

Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HI.

Mol Cancer. 2009 Oct 24;8:91. doi: 10.1186/1476-4598-8-91.

2.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
3.

Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.

Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G.

J Thorac Oncol. 2013 Nov;8(11):1389-95. doi: 10.1097/JTO.0b013e3182a59f45.

4.

MicroRNAs dysregulation in human malignant pleural mesothelioma.

Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, Martini F, Tognon MG.

J Thorac Oncol. 2011 May;6(5):844-51. doi: 10.1097/JTO.0b013e31820db125.

5.

Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.

Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II.

Ann Oncol. 2014 Jun;25(6):1184-92. doi: 10.1093/annonc/mdu127. Epub 2014 Mar 24.

6.

ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.

Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G.

J Thorac Oncol. 2013 Oct;8(10):1317-28. doi: 10.1097/JTO.0b013e3182a0840a.

7.

Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.

Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, Bueno R.

Am J Pathol. 2005 Jun;166(6):1827-40.

8.

Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.

Greillier L, Tounsi A, Berenguer-Daizé C, Dussault N, Delfino C, Benyahia Z, Cayol M, Mabrouk K, Garcia S, Martin PM, Barlesi F, Ouafik L.

J Thorac Oncol. 2016 Jan;11(1):94-107. doi: 10.1016/j.jtho.2015.09.004.

9.

Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.

Kato T, Lee D, Wu L, Patel P, Young AJ, Wada H, Hu HP, Ujiie H, Kaji M, Kano S, Matsuge S, Domen H, Kaga K, Matsui Y, Kanno H, Hatanaka Y, Hatanaka KC, Matsuno Y, de Perrot M, Yasufuku K.

Int J Oncol. 2016 Aug;49(2):448-56. doi: 10.3892/ijo.2016.3566. Epub 2016 Jun 7.

PMID:
27279560
10.

BAP1 protein is a progression factor in malignant pleural mesothelioma.

Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH.

Pathol Oncol Res. 2014 Jan;20(1):145-51. doi: 10.1007/s12253-013-9677-2. Epub 2013 Aug 22.

PMID:
23963927
11.

Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma.

Christensen BC, Godleski JJ, Marsit CJ, Houseman EA, Lopez-Fagundo CY, Longacker JL, Bueno R, Sugarbaker DJ, Nelson HH, Kelsey KT.

Carcinogenesis. 2008 Aug;29(8):1555-9. doi: 10.1093/carcin/bgn059. Epub 2008 Feb 28.

12.

KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.

Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.

Mol Cancer. 2016 Jun 1;15(1):44. doi: 10.1186/s12943-016-0529-z.

13.

Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.

Edakuni N, Ikuta K, Yano S, Nakataki E, Muguruma H, Uehara H, Tani M, Yokota J, Aizawa H, Sone S.

Oncol Res. 2006;16(5):235-43.

PMID:
17294804
14.

Tumour suppressor Fus1 provides a molecular link between inflammatory response and mitochondrial homeostasis.

Uzhachenko R, Issaeva N, Boyd K, Ivanov SV, Carbone DP, Ivanova AV.

J Pathol. 2012 Aug;227(4):456-69. doi: 10.1002/path.4039. Epub 2012 Jun 6.

PMID:
22513871
15.

Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.

Mohr S, Keith G, Galateau-Salle F, Icard P, Rihn BH.

Biochim Biophys Acta. 2004 Jan 20;1688(1):43-60.

16.

Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.

Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, Carosi MA, Blandino R, Panebianco V, Facciolo F, Visca P, Volinia S, Muti P, Strano S, Croce CM, Pass HI, Blandino G.

Oncogene. 2014 Nov 13;33(46):5319-31. doi: 10.1038/onc.2013.476. Epub 2013 Nov 18.

17.

Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.

Dragon J, Thompson J, MacPherson M, Shukla A.

J Cell Biochem. 2015 Aug;116(8):1540-52. doi: 10.1002/jcb.25095.

18.

Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA.

PLoS One. 2012;7(4):e34833. doi: 10.1371/journal.pone.0034833. Epub 2012 Apr 25.

19.

Pathological and molecular biological approaches to early mesothelioma.

Tsujimura T, Torii I, Sato A, Song M, Fukuoka K, Hasegawa S, Nakano T.

Int J Clin Oncol. 2012 Feb;17(1):40-7. doi: 10.1007/s10147-011-0369-1. Epub 2012 Jan 12. Review.

PMID:
22237727
20.

Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.

Betti M, Casalone E, Ferrante D, Aspesi A, Morleo G, Biasi A, Sculco M, Mancuso G, Guarrera S, Righi L, Grosso F, Libener R, Pavesi M, Mariani N, Casadio C, Boldorini R, Mirabelli D, Pasini B, Magnani C, Matullo G, Dianzani I.

Cancer Lett. 2017 Oct 1;405:38-45. doi: 10.1016/j.canlet.2017.06.028. Epub 2017 Jul 4.

Supplemental Content

Support Center